|
19.02.2020 09:10:00
|
Invitation - Orexo Capital Markets Day, Stockholm, Sweden, March 17
UPPSALA, Sweden, Feb. 19, 2020 /PRNewswire/ -- Orexo AB (publ.), today invites investors, analysts and media to attend the company's Capital Markets Day, taking place in Stockholm, Sweden, on
March 17, at Helio GT30, Grev Turegatan 30.
Members of Orexo's management team, including recently appointed EVP Digital Therapeutics, Dennis Urbaniak, will provide an update on the company's strategy, R&D pipeline and business opportunities within digital health. Also speaking will be Dr. Mario Weiss, CEO and Founder of GAIA AG, a global leader in digital therapeutics.
The agenda for the day is displayed below. To register for the event please use the following link
https://financialhearings.com/event/12588/register/live_event
Time pm CET | Topic or activity | Presenter | |
1:00 -1:30 | Registration and coffee | ||
Part 1 - Growth Strategy | |||
1:30 - 1:50 | Strategy for short- and long-term growth | Nikolaj Sørensen, CEO and | |
1:50 - 2:10 | Growing the Zubsolv® franchise | Robert DeLuca, President of | |
Part 2 - Pharma R&D Pipeline | |||
2:10 - 2:30 | A pipeline with significant future potential | Johannes Doll, EVP and | |
2:30 - 2:35 | Q&A session | ||
2:35 - 2:45 | Break | ||
Part 3 - Digital Therapeutics (DTx) | |||
2:45 - 3:10 | DTx - new frontiers in patient care | Dennis Urbaniak, | |
3:10 - 3:40 | GAIA - a global leader in digital | Dr. Mario Weiss, CEO and founder
Nikolaj Sørensen, CEO and | |
3:40 - 3:55 | Q&A session | ||
3:55 - 4:00 | Concluding remarks | ||
4:00 | Mingle and buffet |
Robert Rönn, VP and Head of R&D, and Mike Sumner, Chief Medical Officer, will attend the
Q&A sessions.
Minor changes can be done in the agenda ahead of the event.
About Orexo
Orexo develops and commercializes improved pharmaceuticals and digital therapeutics, addressing unmet medical needs mainly within the growing space of addiction. Approved products are commercialized by Orexo in the US or worldwide via partners. Orexo's main market is the US for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv®, for the treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 844.8 million and the number of employees was 128. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
The information was submitted for publication at 8:00 am CET, on February 19, 2020.
For further information, please contact:
Orexo AB (publ.)
Lena Wange
IR and Communications Manager
Tel: +46-(0)18-780-88-00
Email: ir@orexo.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/orexo/r/invitation---orexo-capital-markets-day--stockholm--sweden--march-17,c3038855
The following files are available for download:
https://mb.cision.com/Main/694/3038855/1196413.pdf | Invitation â€" Orexo Capital Markets Day, Stockholm, Sweden, March 17 |
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Orexo ABShsmehr Nachrichten
|
23.10.24 |
Ausblick: Orexo A präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) | |
|
09.10.24 |
Erste Schätzungen: Orexo A stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
|
16.07.24 |
Ausblick: Orexo A legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
|
02.07.24 |
Erste Schätzungen: Orexo A präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Orexo ABShsmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.